tariquidar has been researched along with bortezomib in 2 studies
Studies (tariquidar) | Trials (tariquidar) | Recent Studies (post-2010) (tariquidar) | Studies (bortezomib) | Trials (bortezomib) | Recent Studies (post-2010) (bortezomib) |
---|---|---|---|---|---|
210 | 16 | 138 | 6,868 | 860 | 4,753 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arnold, ES; Burnett, BG; Fischbeck, KH; Foran, E; Hall, MD; Kwon, DY; Nofziger, JH | 1 |
Azab, AK; Azab, F; de la Puente, P; Federico, C; Fiala, M; Kusdono, HD; Muz, B; Salama, NN; Vij, R | 1 |
2 other study(ies) available for tariquidar and bortezomib
Article | Year |
---|---|
CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.
Topics: Age Factors; Animals; Animals, Newborn; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bortezomib; Central Nervous System; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Hyaluronan Receptors; Mice; Mice, Transgenic; Motor Neurons; Proteasome Endopeptidase Complex; Quinolines; Time Factors; Transfection | 2016 |
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Quinolines | 2017 |